Navigation Links
Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
Date:2/22/2013

NEW YORK, Feb. 22, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the Citigroup 2013 Global Healthcare Conference, being held February 25-27, 2013, in New York City.  Mr. Bentsur's presentation is scheduled to take place on Wednesday, February 27th, at 2:15 PM ET. 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3 clinical program for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit an NDA with the FDA and a MAA with the EMA in the second quarter of 2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in <
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
2. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
8. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
9. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
10. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
11. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HILL, S.C. , Sept. 18, 2014   3D ... addition of the Simbionix RobotiX Mentor™ , a new ... shown for the first time at the ERUS exhibition in ... to 19 (booth #7). Robotic-assisted minimally invasive surgery ... increased demand means the needs for training for robotic surgery ...
(Date:9/18/2014)... , Sept. 18, 2014 Veterinary biologic ... Dr. Ashraf Hanna , M.D., Ph.D., and Dr. ... of Directors. Dr. Hanna is the Vice President of ... Financial Officer for the Genentech Foundation, while Dr. McCracken ... of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... MYRTLE BEACH, S.C., Sept. 19, 2011 Laser ... has received an FDA approval for its revolutionary laser ... treats pain through nerve tissue regeneration. ... trigeminal nerve in the face. The trigeminal nerve (the ...
... 19, 2011 Bayer HealthCare, one of the world,s ... to support the Women,s International Leadership (WIL) Program at ... that Bayer HealthCare has established as part of its ... to further develop an environment that fosters the development ...
Cached Medicine Technology:FDA Approved, Non-Invasive Laser Is A Success in Trigeminal Neuralgia Pain Treatment 2International House and Bayer HealthCare Partner to Prepare Women for Leadership Positions 2International House and Bayer HealthCare Partner to Prepare Women for Leadership Positions 3
(Date:9/18/2014)... that elderly men should not be routinely screened for ... a new study led by researchers at Henry Ford ... in JAMA Internal Medicine , focused on the ... for prostate cancer., "We found that the effect of ... men in particular has been minimal at best," says ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 ChopChop ... Bill Yosses and Yonah Kalikow, 10-year-old Massachusetts’s winner of the ... twist on hummus, the classic Middle Eastern bean dip. Watch ... stage how kids can create their own healthy dips at ... at the third annual Let’s Talk About Food Festival ...
(Date:9/18/2014)... Technology Association of Georgia in collaboration with TAG ... Savvy Awards this week at a special ceremony held ... Downtown Atlanta. The event celebrates Georgia’s best and brightest ... with the 2014 TAG Social Savvy People’s Choice Award ... 6 other award categories: , ,     UPS ...
(Date:9/18/2014)... 18, 2014 Once again, Hickman’s Family ... restaurants around the Valley to celebrate PJs & Eggs. ... Egg Day”: Friday, October 10, 2014. The “breakfast for ... to benefit Arizona’s Children Association (AzCA) foster care programs ... at each participating restaurant on October 10 are invited ...
(Date:9/18/2014)... cancer-hampering molecules show promise in slowing the progression ... often linked to asbestos. Scientists from Case Western ... demonstrate that application of curcumin, a derivative of ... of a protein inhibitor known to combat the ... the Aug. 14 online edition Clinical Cancer ...
Breaking Medicine News(10 mins):Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 3Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3Health News:October 10th Is 6th Annual PJs & Eggs: Hickman’s Family Farms and Breakfast Restaurants Partner to Benefit Arizona Foster Children 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 3
... ShopAtHome.com, a leading Free Coupon and Cash Back ... 1, 2009 to help shoppers shop, save, and donate! ... Komen for the Cure® as part of a month-long ... http:// href="http://www.newscom.com/cgi-bin/prnh/20091001/LA85003LOGO"> www.newscom.com/cgi-bin/prnh/20091001/LA85003LOGO ) , ...
... CITY, Mo., Oct. 1 DST Systems, Inc. (NYSE: ... Company has entered into separate privately negotiated exchange agreements ... principal of the Company,s outstanding 4.125% Series A Convertible ... in aggregate principal of new 4.125% Series C Convertible ...
... recent study published in the October 2009 issue of the ... specific genetic markers identified in previous research, or SNPs, may ... in whites. The genes CHRNA3 and CHRNA5 may contribute to ... nicotine dependence. Although their presence is less frequent in African ...
... Many patients urgently admitted to hospital with cerebral infarction ... prolonged period prior to suffering their stroke, is shown ... the Sahlgrenska Academy at the University of Gothenburg and ... published in the scientific journal BMC Medicine . ...
... they get less sleep than they actually do, study finds ... longer and better than older men, even though many women ... found. , The study of 956 people, aged 59 to ... men on all of the self-reported measures, including a 13.2 ...
... Attacks New York Department of ,Hype, with New York Times Ad ... (CCF) is running a full-page ad in the New York Times ... Department of Health,s hyperbolic "Don,t drink yourself fat" PSA campaign. The Center ... News and New York Post that ask New Yorkers, ...
Cached Medicine News:Health News:ShopAtHome.com Helps Shoppers Save Money and Support Breast Cancer Research 2Health News:DST Systems, Inc. Announces Exchange Transaction Involving 4.125% Series A Convertible Senior Debentures 2Health News:Lung cancer risk increases with expression of specific genes 2Health News:Severe stress can cause stroke 2Health News:Older Women May Sleep Better Than Men 2Health News:Consumer Group Continues Million Dollar Campaign Responding to NYC Health Officials' Hyperbolic PSA Campaign 2
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Curette, 145 mm...
Bone Currettes...
Medicine Products: